Benzodiazepines are commonly used to provide sedation for infants and children undergoing intensive care or diagnostic and therapeutic procedures in a variety of clinical settings. This chapter focuses on Midazolam as representative of this class of drug. Midazolam provides sedation by altering the neuroinhibitory pathway mediated by gammaaminobutyric acid. It is primarily metabolized by the hepatic cytochrome P450 enzyme subfamily and eliminated via the renal route. Plasma clearance of midazolam is affected by the degree of hepatic and renal immaturity in the newborn period. In addition, there is a large inter-individual variability in midazolam metabolism in neonates and children, leading to heterogeneity in drug handling.Pediatric patients, especially neonates, are therefore susceptible to adverse effects associated with the use of midazolam. Transient neurologic, respiratory and cardiovascular reactions have been reported. Although most appeared to be transient, some studies suggest that neonates exposed to midazolam may have longer-term adverse neurodevelopmental effects. Furthermore, in review of literature to date, even though midazolam infusion is efFicacious in sedating critically ill infants and children undergoing intensive care, the use of midazolam for procedural sedation in the pediatric population may be less efficacious than alternatives such as ketamine and may not be appropriate in all clinical circumstance. Therefore, until further research is done on the safety and efficacy of midazolam administration in infants and children, cautious use of this medication in this population is recommended.